인사이트
Insights From Our Experts
Articles
Assessing Market Opportunity and Entry Challenges in Mental Health Disorders
Although mental health disorders affect almost 264 million people worldwide, they are often misunderstood and misdiagnosed, and access is poor. The World Health Organization (WHO) reports that 80% of people in low- and middle-income countries receive…
Getting Treatments to Patients When They Need Them Most: Next Gen Commercialization in Oncology
Commercializing oncology products is extremely complex, but successfully launching new therapies to market is essential for patients and providers in the fight against cancer. In 2020, about 10 million people died from cancer, proving even in…
Novel Antibiotic Opportunity in China
China, with its large population and extensive healthcare system, is the second-highest user of antibiotics in the world. Such widespread use has inevitably led to high levels of antibiotic resistance in the population. When isolated, it…
TOP NEWS: CMS Proposes Repeal on Medicare Coverage of Innovative Technologies Initiative
In a reversal of its upcoming policy to cover breakthrough designated medical devices, the Centers for Medicare and Medicaid Services (CMS) on Monday issued a proposed rule that would completely repeal the Medicare Coverage of Innovative…
Simplifying EU Distribution to Maximize Cost Efficiency and Speed to Market for Patients and Manufacturers
Posted by
Franjo Hanzl on 9월 14, 20219/14/21
COVID-19 ignited a spark of innovation in the healthcare industry, forcing global markets to reconsider drug development and commercialization processes. The European Union (EU), specifically, is taking carefully planned steps into a new phase of pharma…
BLOG: Targeting the ‘Right’ Patient — How Pharmaceutical Companies Can Help Physicians Connect Patients to the Right Treatments
Posted by
Dr. Richard Stefanacci on 9월 10, 20219/10/21
Not every drug is right for every patient, but for some — or the “right” patient — treatment can provide significant clinical and financial benefits. For new therapies, identification of the right patient can be a…
Adapting Patient Access Programs to Asia
In Western markets, pharmaceutical companies have developed many approaches to patient access programs (PAPs), normally emphasizing initiatives that, while helping patients, also support pricing and reimbursement initiatives, such as: Early access programs before market authorization. Financial…
BLOG: Medication Adherence Opportunities and Challenges
Posted by
Dr. Richard Stefanacci on 8월 20, 20218/20/21
“Drugs don’t work in patients who don’t take them.” − Former U.S. Surgeon General C. Everett Coop While it seems obvious, the amount of attention given to adherence is extremely low, especially in comparison to the high costs associated with non-adherence.…
Realign Access Strategies to Overcome Challenges of Co-pay Assistance and Cost Sharing Trends
Kevin O’Meara, EVERSANA’s Vice President of Patient Services Solutions, joined Peter Avalos, National Reimbursement Director at Daiichi Sankyo, Inc., to discuss the current challenges impeding patient access and how to best optimize your co-pay programs using customized solutions and digital innovations.
American Medical Association Discusses New CPT Codes to Identify Digital Health Services
In our last update, we discussed the proposed rule that the Centers for Medicare and Medicaid Services (CMS) issued regarding the addition of certain Current Procedural Terminology (CPT®) codes to identify remote therapeutic monitoring (RTM) in…